CVRx (CVRX)
NASDAQ:CVRX
Want to see CVRX full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.57Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a broadly constructive operational and commercial picture: strong top-line growth (+20% total, +22% U.S.), margin expansion (87% gross margin), ASP improvement and clear progress on the major clinical trial (BENEFIT-HF) and reimbursement milestones (Category I CPT code). Near-term headwinds are primarily administrative and timing-related (Medicare Advantage prior authorization volatility), plus continued operating losses and elevated operating expense guidance. The positives — revenue acceleration, improving gross margin, clinical trial activation, and reimbursement progress — outweigh the short-term challenges, which management characterizes as addressable and temporary.Company Guidance
Total Revenue Growth
Total revenue of $14.8M in Q1 2026, up $2.4M or 20% year-over-year, driven primarily by U.S. growth.
U.S. Performance
U.S. revenue of $13.7M, up $2.5M or 22% year-over-year; expansion of U.S. footprint to 56 sales territories (from 53 at year-end 2025 and 45 on 03/31/2025) and active implanting centers increased to 257 (from 252 at 12/31/2025).
Gross Profit and Margin Expansion
Gross profit of $12.9M, up $2.6M or 25% year-over-year; gross margin improved to 87% versus 84% a year ago, driven by higher average selling price and lower cost per unit from improved manufacturing efficiency.
Average Selling Price (ASP) Improvement
U.S. ASP near $32k in Q1 (up from ~ $31.5k in 2025); company expects to target ~$31–31.5k for full-year 2026 while incentivizing sales to capture higher ASPs.
Clinical Program Advancement — BENEFIT-HF
Activated first site in BENEFIT-HF and enrolled first patient in Q1; trial could expand prevalence-based addressable market from ~339k to >980k patients (potentially tripling TAM to approx. $30B) if successful.
Reimbursement Milestone — Category I CPT Code
Transition to Category I CPT codes effective Jan 1 (described as the most significant reimbursement advancement in company history); 30-day Medicare Advantage prior authorization approval rate improved to 46% YTD 2026 (vs 31% in 2024 and 44% in 2025).
Profitability Trend — Narrowing Net Loss
Net loss improved to $13.1M ($0.50/share) in Q1 2026 from $13.8M ($0.53/share) in Q1 2025; cash and cash equivalents of $72.3M as of 03/31/2026 and net cash used in operating & investing activities of $12.3M (slightly improved from $12.9M prior-year).
Commercial Organization Momentum
Company reports a broader, more experienced sales organization and continued program-focused execution with early indications of higher utilization in targeted accounts as Barostim becomes more routinely integrated into heart failure management workflows.
CVRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CVRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $6.92 | $5.27 | -23.84% |
Feb 12, 2026 | $5.69 | $4.95 | -13.01% |
Nov 05, 2025 | $9.79 | $10.05 | +2.66% |
Aug 04, 2025 | $7.55 | $6.80 | -9.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CVRx (CVRX) report earnings?
CVRx (CVRX) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).
What is CVRx (CVRX) earnings time?
CVRx (CVRX) earnings time is at Aug 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVRX EPS forecast?
CVRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.52.